GPT‑Rosalind for life science

Drug discovery starts with a slow search through papers, databases, and lab results, and OpenAI says GPT‑Rosalind is built to speed that work. (openai.com) OpenAI announced GPT‑Rosalind on April 16, 2026 as a “frontier reasoning model” for biology, drug discovery, and translational medicine, the stage that tries to turn lab findings into treatments. Reuters reported the release the same day. (openai.com) (reuters.com) The company said the model is tuned for scientific workflows across chemistry, protein engineering, and genomics, and can help with evidence synthesis, hypothesis generation, experimental planning, literature review, and data analysis. OpenAI said researchers can use it to query databases, read recent papers, call scientific tools, and suggest new experiments. (openai.com) (reuters.com) In plain terms, biology research is often a matching problem: scientists connect genes, proteins, molecules, pathways, and diseases, then test which links hold up in the lab. OpenAI said GPT‑Rosalind performs best on tasks that require reasoning across those biological building blocks in multi-step workflows. (openai.com) OpenAI tied the product to the long economics of drug development, saying it often takes about 10 to 15 years to move from target discovery to regulatory approval in the United States. The company’s pitch is that better early guesses can improve later experiments and reduce wasted work. (openai.com) The release is aimed at research organizations, not general consumers. OpenAI said GPT‑Rosalind is available as a research preview in ChatGPT, Codex, and the application programming interface for qualified customers through its trusted access program. (openai.com) (reuters.com) OpenAI is also releasing a free Life Sciences research plugin for Codex that it said connects to more than 50 scientific tools and data sources. That matters because lab work is usually split across separate software, file formats, and reference databases. (openai.com) The company said it is already working with Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific on research workflows. OpenAI’s broader life-sciences business page also pitches enterprise tools for research and development, clinical, regulatory, and manufacturing teams. (openai.com 1) (openai.com 2) The model is named after Rosalind Franklin, whose research helped reveal DNA’s structure. With GPT‑Rosalind, OpenAI is putting that name on a product meant for the part of science that happens before any drug reaches patients. (openai.com)